Adaptimmune Therapeutics PLC — Director's Dealing 2020

Jul 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-06-29

Reporting Person: Wood Gavin (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-29	Ordinary Shares with a nominal value of GBP0.001 per share	P	33000	$1.62	Acquired	33000	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2: The 33,000 ordinary shares reported in Column 4 are represented by 5,500 ADSs.

F3: The price reported in Column 4 of $1.62 per ordinary share is derived from the purchase price paid on June 29, 2020 of $9.7497 per ADS divided by six.